Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Meet the Managing Partner – Q&A with Goodwin’s Mark Bettencourt (<i>Boston Bar Association</i>)

main

12_02 Meet the Partner_Q A with Mark Bettencourt

In the Press: Meet the Managing Partner – Q&A with Goodwin’s Mark Bettencourt (Boston Bar Association)

Meet the Managing Partner – Q&A with Goodwin’s Mark Bettencourt (Boston Bar Association)

Related Content

FDA Approves Shanghai Henlius Biotech IND for Cetuximab Biosimilar

FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch

International Biosimilars Updates

FDA Signals Potentially Evolving Stance Toward Compounding of Certain Peptides

Third Circuit Affirms Denial of Stelara Biosimilar Injunction

FDA Approves Lannett, Lanexa Biologics, and Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar

FDA Issues Draft Guidance on Safety Testing for Gene Editing Therapies

Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 Billion

Goodwin Advises Anagram Therapeutics on $250 Million Investment from Blackstone Life Sciences

Goodwin Guides Avalo Therapeutics on Pricing of $430 Million Public Offering

Goodwin Advises CellCentric on Oversubscribed $220 Million Series D Financing

Goodwin Advises Seaport Therapeutics on Pricing of $254.9 Million Upsized Initial Public Offering

Goodwin Advises Intellia Therapeutics on $194.6 Million Pricing of Public Offering of Common Stock

Goodwin Guides Cytospire Therapeutics on Oversubscribed $83 Million Series A Financing

Goodwin Advises Perfuse Therapeutics on $2.45 Billion Acquisition by Bayer

Paul Rosie Joins Goodwin’s Life Sciences Group in Boston

Life Sciences